Patents by Inventor Daniel D. Long

Daniel D. Long has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodrugs of fencamfamine
    Patent number: 11919836
    Abstract: Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: March 5, 2024
    Assignee: Praxis Bioresearch, LLC
    Inventors: Sandeep Patil, Ron Bihovsky, Steven A Smith, Yuhua Ji, Valentino Stella, Daniel D. Long, Daniel Marquess
  • Ester and carbonate pyrimidine compounds as JAK kinase inhibitors
    Patent number: 11845747
    Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory skin diseases and other diseases.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: December 19, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Philip A. Gerken, Jianhua Chao, Daniel D. Long
  • DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS
    Publication number: 20230322774
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.
    Type: Application
    Filed: March 9, 2023
    Publication date: October 12, 2023
    Inventors: Daniel D. Long, Cameron Smith, Corbin Thompson
  • Prodrugs of fencamfamine
    Patent number: 11731935
    Abstract: Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: August 22, 2023
    Assignee: Praxis Bioresearch, LLC
    Inventors: Sandeep Patil, Ron Bihovsky, Steven A Smith, Yuhua Ji, Valentino Stella, Daniel D. Long, Daniel Marquess
  • 5 to 7 membered heterocyclic amides as JAK inhibitors
    Patent number: 11713315
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: August 1, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, Cameron Smith, Corbin Thompson
  • 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20230183232
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: December 9, 2022
    Publication date: June 15, 2023
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang
  • Dimethyl amino azetidine amides as JAK inhibitors
    Patent number: 11634419
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: April 25, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, Cameron Smith, Corbin Thompson
  • Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
    Patent number: 11608354
    Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: March 21, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Daniel D. Long, Donna A. A. Wilton, Mandy Loo, Patrick J. Brassil
  • 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
    Patent number: 11548887
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: January 10, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang
  • BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
    Publication number: 20220274957
    Abstract: The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: January 12, 2022
    Publication date: September 1, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Roland Gendron, Lan Jiang, Seok-Ki Choi, Daniel D. Long, Paul R. Fatheree, Daniel Marquess
  • ESTER AND CARBONATE PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20220009926
    Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory skin diseases and other diseases.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 13, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Philip A. Gerken, Jianhua Chao, Daniel D. Long
  • Ester and carbonate pyrimidine compounds as JAK kinase inhibitors
    Patent number: 11155549
    Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory skin diseases and other diseases.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: October 26, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Philip A. Gerken, Jianhua Chao, Daniel D. Long
  • Prodrugs of a JAK Inhibitor Compound for Treatment of Gastrointestinal Inflammatory Disease
    Publication number: 20210179655
    Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.
    Type: Application
    Filed: February 22, 2021
    Publication date: June 17, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Daniel D. Long, Donna A.A. Wilton, Mandy Loo, Patrick J. Brassil
  • DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS
    Publication number: 20210155620
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.
    Type: Application
    Filed: February 4, 2021
    Publication date: May 27, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, Cameron Smith, Corbin Thompson
  • Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
    Patent number: 10961267
    Abstract: The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: March 30, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Ryan Hudson, Daniel D. Long, Donna A. A. Wilton, Mandy Loo, Patrick J. Brassil
  • Dimethyl amino azetidine amides as JAK inhibitors
    Patent number: 10947229
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: March 16, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, Cameron Smith, Corbin Thompson
  • GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS
    Publication number: 20210032250
    Abstract: The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
    Type: Application
    Filed: July 13, 2020
    Publication date: February 4, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: DANIEL D. LONG, DONNA A.A. WILTON, MANDY M. LOO
  • 5 TO 7 MEMBERED HETEROCYCLIC AMIDES AS JAK INHIBITORS
    Publication number: 20210024517
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds and methods of using such compounds to treat respiratory diseases.
    Type: Application
    Filed: October 13, 2020
    Publication date: January 28, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, Cameron Smith, Corbin Thompson
  • 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20210024515
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: July 7, 2020
    Publication date: January 28, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Daniel D. Long, John R. Jacobsen, Lan Jiang
  • PRODRUGS OF FENCAMFAMINE
    Publication number: 20200399203
    Abstract: Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.
    Type: Application
    Filed: April 14, 2020
    Publication date: December 24, 2020
    Inventors: Sandeep Patil, Ron Bihovsky, Steven A. Smith, Yuhua Ji, Valentino Stella, Daniel D. Long, Daniel Marquess